Clinical and microbiological characterization of pneumonia in mechanically ventilated patients  by Medell, Manuel et al.
braz j infect d i s . 2012;16(5):442–447
The Brazilian Journal of
INFECTIOUS DISEASES
www.elsev ier .com/ locate /b j id
Original article
Clinical and microbiological characterization of pneumonia
in mechanically ventilated patients
Manuel Medell a, Marcia Harta, Odalys Marrerob, Fidel Espinosaa,
Zurelys Montes de Ocaa, Rodolfo Valdésc,∗
a Microbiology Department, Hermanos Ameijeiras Hospital, Havana, Cuba
b Intensive Cares Unit, Hermanos Ameijeiras Hospital, Havana, Cuba
c Genetic Engineering and Biotechnology Center, Havana, Cuba
a r t i c l e i n f o
Article history:
Received 25 March 2012
Accepted 2 June 2012
Available online 10 September 2012
Keywords:
Antibacterial agents
Pneumonia
Respiratory care units
a b s t r a c t
Objective: To characterize mechanical ventilation-associated pneumonia (MVAP).
Method: This is an observational descriptive study to characterize MVAP in 61 ventilated
patients admitted in the intensive care units of the Hermanos Ameijeiras hospital during
2011. This study also aimed to isolate the bacteria causing MVAP and characterize their
resistance to antibiotics.
Results: 51 (83.60%) patients presented pulmonary inﬁltrates and 35 (50.81%) presented a
clinical score ≥ 6 according to the Clinical Pulmonary Infection Score. Acinetobacter bau-
mannii and Pseudomonas aeruginosa were the most frequently isolated microorganisms from
patients with MVAP. Both microorganisms showed a high resistance to antibiotics. Car-
bapenems were the most frequent used antimicrobial therapeutic agents; elective antibiotic
combinations were directed against both bacterial wall structure and nucleic acid synthesis.
Conclusion: Patients with MVAP identiﬁed during the studied period showed similar fre-
quency to those reported in medical literature. Thus, this study corroborated that this is
still a relevant medical problem in this hospital. Acinetobacter baumannii and Pseudomonas
aeruginosa were the most frequently isolated microorganisms from patients with MVAP.
Antimicrobial treatment, empirical or not, are still the main risk factors for the development
ofmultidrug-resistant strains of bacteria. The rate of resistance to antibiotics ofAcinetobacter
baumannii and Pseudomonas aeruginosa strains isolated from patients with MVAP was higherthan those isolated from infected patients without MAVP. Tigecycline and colistin were the
only antibiotics fully effective against Acinetobacter baumannii strains isolated in 2011 from
patients with MVAP; against Pseudomonas aeruginosa strains, only colistin was fully effective.
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND∗ Corresponding author. Monoclonal Antibody Department, Genetic Eng
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ntroduction
echanical ventilation-associated pneumonia (MVAP)
ccounts for approximately 80% of nosocomial pneumo-
ia episodes. This term is applicable only in intubated or
racheostomized patients who develop pneumonia under
echanical ventilation.1 The mechanical ventilation proce-
ure was ﬁrst used in animals in 1543 by Andreas Vesalius.
alen was the ﬁrst physician to describe its use in humans.2
MVAP is one of the most common infections in the inten-
ive care units (ICUs), increasing the length of stay of patients
n these units, the cost of the treatment, and the risk of
eath.3 The etiology of MVAP depends on multiple factors
uch as time of ventilation, prior administration of antibiotics,
resence of chronic obstructive pulmonary disease, coma,
nd local factors.4 Various microbial agents such as non-
ermentative Gram-negative multidrug-resistant Acinetobacter
aumannii and Pseudomonas aeruginosa have been described,
ver the last decades, as agents that cause this type of
echanical ventilation-associated infection.5
The main mechanism in the pathogenesis of MVAP is
ased on the repeated micro-aspiration of microorganisms
hat colonize the upper airways through the space between
he endotracheal tube cuff and trachea wall. The origin of
hese microorganisms varies from the patient’s endogenous
icrobiota to exogenous sources, mainly the hands of health-
are workers or contaminated nebulizers.6–8
bjectives
ue to the importance of MVAP and the consequences for
atient survival and healthcare costs, a study to character-
ze MVAP is performed in the Hermanos Ameijeiras Hospital
HAH) annually. This article discusses the data collected in the
ear 2011. Thus, themain objectives of this studywere to char-
cterize MVAP, to isolate antimicrobial agents in tracheal ﬂuid
amples, to identify most frequent causative microorganisms,
nd to calculate the resistance rate to antibiotics of the most
requently isolated microorganisms responsible for MVAP in
CU patients.
aterials and methods
eneral information of hospital
heHAH is located inHavana, Cuba. It has 625 beds, 15 special-
zed services, and 12 surgical units, as well as three ICUs. The
nstitution provides care to the adult population exclusively.
niverse of patients
ll ventilated patients in the ICU was considered as the uni-
erse of the study.
riteria for patient inclusionll ventilated patients admitted in the ICU during 2011 with
vailable tracheal aspirates for microbiological testing were
ncluded.2;16(5):442–447 443
Statistical analysis
Clinical data were gathered in a data base model (Statistical
Package for Social Sciences – SPSS.17) designed by the Micro-
biology Department. Data processing was performed using
the Excel software and the statistical software Statgraphics
Plus version 5.0 (2000). Pearson’s chi-squared test was used to
analyze the association among qualitative variables, and Stu-
dent’s t-testwas performed to compare the number of isolated
strains and the resistance to antibiotics. The signiﬁcance level
was set at 0.05.
Criteria for the clinical diagnosis of MVAP
Clinical diagnosis of MVAP was performed following the Clin-
ical Pulmonary Infection Score (CPIS).9 Patients with clinical
scores ≥ 6 were considered positive for MVAP.
Sample processing and microorganism identiﬁcation
The processing of the samples for microbiological diagnosis
was performed according to the norms and procedures of
the Centers for Disease Control (CDC).10 The diagnosis of the
microorganisms was performed using the Vitek 2 Compact
automated equipment (bioMériux – France).
This is an antimicrobial resistance study of Acinetobacter
baumannii and Pseudomonas aeruginosa strains isolated from
patients with or without MAVP.
In order to test the antimicrobial resistance to antibi-
otics, the Vitek 2 Compact automated equipment (bioMériux
– France) was used with AST N87 cards. The antimicro-
bials assessed to compare the resistance of the Acinetobacter
baumannii and Pseudomonas aeruginosa strains isolated from
patients with and without MVAP were: amikacin (10g),
ampicillin (10g), ampicillin-sulbactam (10g-10g), aztroe-
nam (30g), cefepime (30g), cefoxitine (30g), ceftazidime
(30g), ceftriaxone (30g), ciproﬂoxacin (5g), colistin (10g),
gentamicin (10g), imipenem (10g), meropenem (30g),
nalidixic acid (30g), and tigecycline (15g). The strains
ATCC BAA-747 (Acinetobacter baumannii) and ATCC 27853 (Pseu-
domonas aeruginosa) were used as reference materials.
Results
From the 61 patients included in this research, 28 (45.9%)
and 23 (37.7%) had diffuse and localized inﬁltrates, respec-
tively, which are relevant signs of MVAP. 35 patients (53.73%)
showed an inﬁltrate score ≥ 6 according to CPIS9 and three
(4.90%) were diagnosed post-ventilation. Polymicrobial iso-
lates were detected in 15 patients (24.59%). Regarding the
studied samples, a total of 156 tracheal aspirates were tested.
Bacterial growth (> 104 ufc/mL) was observed in 128 samples
(82.05%). The average ventilation time was 9.9± 11.9 days and
the average age of the studied patients was 55.5± 17.2 years
old (Table 1).The microorganisms isolated from this universe of
patients with MVAP were: Acinetobacter baumannii, Pseu-
domonas aeruginosa, Escherichia coli, meticillin-resistant Staphy-
lococcus aureus, Stenotrophomonas maltophilia, Pseudomonas
444 braz j infect d i s . 2012;16(5):442–447
Table 1 – Results of the clinical-microbiological
characterization of MVAP.
Total %/a %/b
Patients included in the
study
61 100
Average age of patients
(years)
55.5± 17.2
Mechanical ventilation
average time (days)
9.9± 11.9
Analyzed samples 156 100
Samples with bacterial
growth
128 82.0
Patients with MVAP 35 53.73
Patients with MVAP of
nosocomial origin
18 29.50
Patients with diffuse
inﬁltrates
28 45.90
Patients with localized
inﬁltrates
23 37.70
Patients without
pulmonary inﬁltrates
21 34.42
Table 2 – Proportions of microorganisms isolated from
patients with MVAP (n=51).
Bacteria MVAP episodes %
Single infections
Acinetobacter baumannii 17 33.33
Pseudomonas aeruginosa 12 23.52
Escherichia coli 4 7.84
Methicillin-resistant
Staphylococcus aureus
3 5.88
Stenotrophomonas
maltophilia
2 3.92
Pseudomonas spp. 1 1.96
Klebsiellas pneumoniae 1 1.96
Enterobacter cloacae 1 1.96
Proteus mirabilis 1 1.96
Moraxella lacunata 1 1.96
Vancomycin-resistant
Enterococcus faecalis
1 1.96
Polymicrobial infections
Acinetobacter baumannii +
Pseudomonas aeruginosa
2 3.92
Pseudomonas spp, +
Escherichia coli
1 1.96
Pseudomonas aeruginosa +
Pseudomonas spp.
1 1.96
Acinetobacter baumannii +
Escherichia coli
1 1.96
Stenotrophomonas
maltophilia +
Escherichia coli
1 1.96
Pseudomonas aeruginosa +
Escherichia coli
1 1.96
Total 51 100.00
p (between single and
polymicrobial
infections)
0.2260
p (between A. baumannii 7.5x10-10Patients with
polymicrobial isolates
15 24.50
spp., Klebsiella pneumoniae, Enterobacter cloacae, Proteusmirabilis,
Moraxella lacunata, and vancomycin-resistant Enterococcus fae-
calis. The polimicrobial infections observed were: Acinetobacter
baumannii + Pseudomonas aeruginosa, Pseudomonas spp. +
Escherichia coli, Pseudomonas aeruginosa + Pseudomonas spp.,
Acinetobacter baumannii + Escherichia coli, Stenotrophomonas
maltophilia + Escherichia coli, and Pseudomonas aeruginosa +
Escherichia coli. Table 2 shows the number and proportion
of each isolate in detail. The proportion of infections with
Acinetobacter baumannii and Pseudomonas aeruginosawas signif-
icantly higher than the other isolated bacteria (p = 7.5 x 10−10).
Resistance rates to 15 different antimicrobials of the
Acinetobacter baumanni and Pseudomonas aeruginosa strains iso-
lated from patients with and without MVAP are shown in
Figs. 1 and 2, respectively. Resistance rates to antimicrobials
among isolates ofAcinetobacter baumannii (n = 17)were only dif-
ferent with regard to imipenem, meropenen, and amikacin.
However, no statistically signiﬁcant differences were detected
in any of these cases (p = 0.23). In the case of the Pseu-
domonas aeruginosa isolates, resistance rates to antimicrobials
of the MVAP isolates were higher for ceftazidime, cefepime,
aztreonamm imipinem, meropenem, amikacin, gentamicin,
and ciproﬂoxacin. However, signiﬁcant difference was only
observed for aztreonam (p = 0.03).
Discussion
MVAP is more frequent and severe exhibiting a high
mortality.11 The clinical diagnosis of this disease is established
by the emergence of new or progressive inﬁltrates on chest
radiography, followed by two or three additional criteria rec-
ommended by the CPIS since 1991.9 But today, the importance
of traditional and automated microbiology, as a fundamental
tool for the diagnosis of these infections, is emphasized, par-
ticularly when initiating or changing antimicrobial treatment
and assessing the effectiveness of bacterial quantiﬁcation.12and P. aeruginosa, and
the remaining)
According to literature, 50% to 60% of patients with
mechanical ventilation for over 48h in ICUs developed pneu-
monia, and approximately 52% of these are of nosocomial
origin. Themortality attributed to this type of infection ranged
between 24% to 76% in mechanically ventilated patients for
more than 48h.13,14 These ﬁndings are consistent with those
found in this study, since 53.73% of the patients admitted for
an average of 9.9 ± 14.1 days to the ICU of the HAH developed
MVAP, and out of those, 51.4% had a nosocomial origin. Nev-
ertheless, these results contrast with those of the national
surveys conducted by Labaut et al., who have demonstrated
lower rates of the MVAP than those reported in the HAH,15
despite sharing the same health system and geographical
area.
The etiology of MVAP was described several years ago, and
it varies according to the characteristics of the geographic
area and ICU, and the ventilation time of the patients.14
Gram-negative bacteria, such as Pseudomonas aeruginosa,
Acinetobacter spp. and Enterobacteriaceae, represent from 55%
to 85% of MVAP cases; Staphylococcus aureus, from 20% to 30%;
and 40% to 60% are polymicrobial infections.16
In a recent study performed by Ortiz et al., Pseudomonas
aeruginosa, Klebsiella pneumoniae and Staphylococcus aureus
braz j infect d i s . 201
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Fig. 1 – Resistance rates to antimicrobials of Acinetobacter
baumannii strains isolated from patients with and without
MAVP (n=17, p = 0.2374).
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becomes more limited every day due to bacterial resistanceAVP (n=12, p = 0.1930).
eticillin-sensitive were described as the bacteria associated
o MVAP in 39 ICUs in Colombia.17. Ruiz et al., in another Latin
merican study, identiﬁed methicillin-resistant Staphylococ-
us aureus and polymicrobial infections18 as leading causes of
neumonia in ventilated patients. The MVAP consensus con-
ucted in 2011 established that the microorganisms that most
ommonly affect patients undergoing mechanical ventilation2;16(5):442–447 445
in the ICU were: methicillin-sensitive Staphylococcus aureus,
methicillin-resistant Staphylococcus aureus, Pseudomonas spp.,
Acinetobacter spp., and Enterobacteriaceae.19
Most of the microorganisms reported as causal agents
of MVAP are consistent with those found in the present
study. In this study, 11 different bacteria were isolated from
patients with MVAP. Within these patients, the prevail-
ing bacteria (56.82%) were Acinetobacter baumannii (33.33%)
and Pseudomonas aeruginosa (23.52%). These results are con-
sistent with those reported in 2002 by González et al.
where Acinetobacter baumannii and Pseudomonas aeruginosa
were the main causative microorganisms of MVAP in this
hospital.20 As mentioned above, the proportion of infec-
tions by these two microorganisms was statistically different
than the rest of the isolated bacteria from patients with
MVAP.
As was found in this study, Acinetobacter baumannii has
probably been the most frequently isolated bacterium from
patients with MVAP around the world. Pneumonia caused
by this microorganism is highly related with previous use of
antimicrobials, and contamination of ventilation equipment
and hands of health workers.21,22 It is the authors’ opinion
that antimicrobial treatment, empiric or not, is the principal
risk factor for the development of multidrug-resistant strains
of this bacterium, and thus of the high proportion of contam-
ination in patients with MVAP.
The relative high proportion of infection with Pseudomonas
aeruginosa is in agreement with that reported by others.17,23,24
This ﬁnding has been associated with the possibility that
this microorganism penetrates the lower respiratory tract of
the ventilated patients employing two ways: endogenous and
exogenous,25 and also by the special tropism of Pseudomonas
aeruginosa to the tracheal epithelium, as suggested by Nieder-
man et al.26
The other isolated bacteria (Escherichia coli, methicillin-
resistant Staphylococcus aureus, Stenotrophomonas maltophilia,
Pseudomonas spp., Klebsiella pneumoniae, Enterobacter cloacae,
Proteus mirabilis, Moraxella lacunat, and vancomycin-resistant
Enterococcus faecalis) represented only 29.4% of the infections.
However, around 13.72% of infections were polymicrobial.
Therefore, it should be mentioned that infections of polymi-
crobial origin also play a role in the onset of MVAP, which is
also coincidentwithother reports.16 In that sense, a behavioral
association of Escherichia coli with different species of bacteria
was observed as cause of the MVAP, a phenomenon that was
not found in the examined literature. Several authors have
demonstrated the existence of mixed infections, but they did
not describe the microorganisms in detail.14–18 Perhaps the
association of Escherichia coli with other microorganisms caus-
ing MVAP is associated with the invasive mechanisms and
high prevalence of this enterobacterium in the digestive tract
as part of the intestinal microbiota. In that sense, the use of
nasogastric probes may favor upward migration, colonization,
and infection from the lower airways.
Bacterial resistance is one of the most important problems
that affect hospitals, especially ICUs. Antimicrobial therapymechanisms created by the indiscriminate use of these drugs,
which could turn medicine into an era where there were no
antimicrobials to treat bacterial infections.27
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According to the Infectious Diseases Society of America
and the American Thoracic Society, empiric antimicrobial
treatment is linkedwith the emergence ofmultidrug-resistant
strains, indicating that this practicemust stop and be replaced
by rapid microbiological tests, which will play a crucial role in
the diagnosis of MVAP and in the establishment of appropri-
ate therapies to prevent the emergence of multidrug-resistant
strains and worsening of infection.28 Ruiz C et al., conﬁrmed
that empirical treatment induced the emergence of resistant
strains causing MVAP in their hospital;18 in a retrospective
review conducted in 2002, the empirical antimicrobial treat-
ment in ventilated patients of the HAH was evidenced,19
which could explain the high resistance of the bacteria cur-
rently encountered.
Acinetobacter baumannii is considered one of the leading
bacteria for theproductionofmechanisms that induce antimi-
crobial resistance. Meropenem and imipenem in particular,
are used in the treatment of infections caused by Acine-
tobacter baumannii strains because they have shown higher
in vitro activities than other antimicrobial agents. Neverthe-
less, carbapenem resistance in these species is increasing
signiﬁcantly; it is a sentinel sign for the emergence of
multidrug-resistant strains.29 However, due to several reasons,
antimicrobial resistance results cannot be extrapolated under
any circumstances. For instance, a study conducted in 2005,
which compared strains of Acinetobacter baumannii isolated in
a hospital in Madrid, Spain, with those isolated in a hospi-
tal in Hong Kong, China,30 demonstrated that over 90% of
the isolates obtained from both hospitals were sensitive to
imipenem. This ﬁnding is in contrast with the results of the
present study. In addition, an investigation performed at the
HAH31 also demonstrated that resistance of Acinetobacter bau-
mannii strains to imipenem increased from 2002 to 2010 by
over 80%, and continued increasing in 2011 according to the
results of this study.
A signiﬁcant increasewas also observed in imipenem resis-
tance of the Acinetobacter baumannii strains isolated from the
MVAP-patients of the HAH32 in comparison with the resis-
tance to this antibiotic of strains isolated in a study performed
in Europe and Asia.30
Some upregulation mechanisms of chromosomally medi-
ated efﬂux pumps have been described as causes for the
resistance to tigecycline by other researchers.33 However, tige-
cycline has been reported as an effective antimicrobial agent
against resistant species of Acinetobacter baumannii.34 Thus, it
is used as an effective therapeutic measure in many cases
of serious infection with strains of this microorganism. No
tigecycline-resistant strains of Acinetobacter baumannii were
found in patients with MVAP in this study. Interestingly, one
resistant strain was isolated from a patient with infection but
without MVAP.
Colistin is another option for treating infections by this bac-
terium. It causes alterations in the bacterial cell membrane,
increasing permeability and leading to cell death. Its effect
is dose-dependent, but some cases of resistant Acinetobacter
baumannii strains have already been reported,30,34 possibly as a
result of alterations in the outer cellmembrane or efﬂux pump
mechanisms. However, similarly to tigecycline, no colistin-
resistant strains of Acinetobacter baumannii were detected in
the samples of patients with MVAP.12;16(5):442–447
As a ﬁnal point that is very interesting and not easily
found in the literature, regarding meropenem, imipenem,
and amikacin, a higher percentage of resistance of MVAP-
associated strains with respect to non-MVAP-associated
strains of Acientobacter baumannii was found in this study, so it
could be inferred that resistance to these drugs is an important
risk factor for developing pneumonia by Acinetobacter bauman-
nii in this hospital.
Regarding Pseudomonas aeruginosa, it primarily affects
patients with impaired local or general defense mecha-
nisms against infections; hence, it may be considered as
an opportunistic pathogen. It is the main cause of noso-
comial infections acquired in ICU, because Pseudomonas
aeruginosa is naturally resistant to many commonly used
antimicrobials in clinical practice. In this study, the high
resistance of the Pseudomonas aeruginosa strains isolated from
patients with MVAP was also conﬁrmed. Colistin was the only
antimicrobial completely effective against this bacterium. In
that sense, one could speculate that this resistance may
be due to the permeability barrier provided by its outer
membrane lipopolisaccharide, efﬂux pumps, and plasmid-
mediated antimicrobial resistance, among other factors. Of
interest, although resistance of the strains isolated from
patients with MVAP was higher to aztreonam, ceftazidime,
cefepime, gentamicin, imipenem, amikacin, meropenem, and
ciproﬂoxacin, signiﬁcant differences were only observed with
aztreonam.
One aspect that has been widely discussed in the lit-
erature is the desirability of combined antibiotic therapy
over monotherapy for serious infections by Pseudomonas
aeruginosa.31 Advantages of the combined therapy are the
increase in the possibility that the pathogen is sensitive to
at least one of the two antimicrobials prescribed, the possi-
bility of preventing the development of resistance, and the
synergistic effect of the combination. However, the hypoth-
esis that the combined antibiotic therapy may increase the
risk of toxicity of the treatment, increase costs, and increase
the risk of superinfection, cannot be discarded. However, from
the analysis of the results of this study, the combination of any
antimicrobial assessed here against Pseudomonas aeruginosa is
not recommended. The single antibiotic of choice should be
colistin.
In summary, MVAP detected during the studied period
showed a similar frequency to that reported in medical lit-
erature. Acinetobacter baumannii and Pseudomonas aeruginosa
were the main microorganisms that affected patients with
MVAP. Antimicrobial treatments, empiric or not, are still the
main risk factors for the development of multidrug-resistant
strains. Resistance to antibiotics ofAcinetobacter baumannii and
Pseudomonas aeruginosa strains isolated from patients with
MVAP was higher than in those isolated from patients with
infection but without MAVP. Tigecycline and colistin were the
only antibiotics fully effective against of Acinetobacter bau-
mannii strains. Colistin was the only antibiotic fully effective
against Pseudomonas aeruginosa strains.Conﬂict of interest
All authors declare to have not conﬂict of interest.
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